HeartSciences Named as a Top 10 MedTech Startup 2022 by MedTech Outlook Magazine
October 20, 2022 09:00 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Announces Major Milestone with the Issuance of CPT® Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction
October 19, 2022 09:15 ET
|
Heart Test Laboratories, Inc.
SOUTHLAKE, Texas, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence
September 20, 2022 08:30 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results
September 13, 2022 08:00 ET
|
Heart Test Laboratories, Inc.
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year Southlake, Texas,...
HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital
September 12, 2022 08:30 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company focused on applying innovative AI-based technology...
HeartSciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 08:30 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results
August 01, 2022 08:30 ET
|
Heart Test Laboratories, Inc.
MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year Completed IPO in June 2022 with Approximately $6.375M of Gross Proceeds Listed on NASDAQ Capital Market under Ticker HSCS ...
HeartSciences CEO to Participate in the Benzinga All Access Event on July 15th
July 13, 2022 14:03 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- HeartSciences (NASDAQ: HSCS; HSCSW) (“Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also...
Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing
June 15, 2022 09:50 ET
|
Heart Test Laboratories, Inc.
SOUTHLAKE, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying...